Innate Pharma: positive preclinical data for IPH6501

(CercleFinance.com) - Innate Pharma announces the publication in Science Immunology of positive preclinical data on its next-generation NK cell engager ANKET IPH6501, currently being evaluated in a Phase 1/2 clinical trial in B-cell non-Hodgkin's lymphoma.


According to these data, IPH6501 stimulates NK cell proliferation and cytotoxicity, showing activity against a range of B-cell non-Hodgkin's lymphoma cell lines, including those with low CD20 receptor density.

In vivo studies in non-human primates and mouse tumor models have validated its efficacy and demonstrated that IPH6501 induces migration of peripheral NK cells to the tumor site", adds the biotech company.

Copyright (c) 2024 CercleFinance.com. All rights reserved.